Immune Pharmaceuticals Licenses a Novel Bispecific Antibody Technology
News Dec 29, 2015
Immune Pharmaceuticals Inc. has announced that it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.
Dr. Daniel Teper, CEO of Immune commented, "This is an important milestone as we make progress with our immuno-oncology pipeline. Our research will focus on the application of this novel bispecific platform to target immune checkpoints. Our plan is to generate additional pre-clinical data with selected bispecific drug candidates in 2016."
The R&D work on the bispecific antibodies will be performed in Immune's recently established Immunology R&D unit at the Alexandria Center for Life Sciences in New York City, under the leadership of Dr. Boris Shor, Executive Director of R&D, who joined the company from Pfizer Oncology.
In recently presented data, the platform prototype bispecific antibody was shown to retain effector functions and mediate redirect killing of target cells by cytokine induced killer T cells. The bispecific antibody demonstrated direct anti-cancer effects in vitro, as well as in vivo anti-tumor activity and improved survival in a mouse xenograft model of disseminated leukemia.
A collaborative European consortium led by Dr. Kadouche from Atlante Biotech, and funded by a European grant developed the novel platform for production of tetravalent IgG1-like bispecific antibodies.
No Llamas RequiredNews
Detouring around a major research roadblock, researchers have found a new way to create valuable antibodies without needing … llamas? It is a little-known fact that llamas, alpacas, camels and other members of the camelid family make a unique class of antibodies that allow scientists to determine the structures of otherwise impossible-to-study proteins in the body, helping them to understand how those proteins malfunction in disease and how to design new drugs that act on them.READ MORE
Timing of Measles Vaccine Important for Overall Child Survival RatesNews
In the largest study to date on children in a low/middle income country, research finds that the timing of a measles vaccine in an overall vaccination schedule can have a profound impact on child survival rates beyond protecting against measles infection.READ MORE
Experimental Therapy Restores Nerve Insulation Damaged by DiseaseNews
Lab Tests Show Treatment Might Help People with Autoimmune Diseases.READ MORE